Connecticut v. Physicians Health Services of Connecticut, Inc.

103 F. Supp. 2d 495, 24 Employee Benefits Cas. (BNA) 2589, 2000 U.S. Dist. LEXIS 12191, 2000 WL 978588
CourtDistrict Court, D. Connecticut
DecidedJuly 13, 2000
DocketCIV.A. 3:99CV2402 SR
StatusPublished
Cited by12 cases

This text of 103 F. Supp. 2d 495 (Connecticut v. Physicians Health Services of Connecticut, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Connecticut primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Connecticut v. Physicians Health Services of Connecticut, Inc., 103 F. Supp. 2d 495, 24 Employee Benefits Cas. (BNA) 2589, 2000 U.S. Dist. LEXIS 12191, 2000 WL 978588 (D. Conn. 2000).

Opinion

*497 RULING ON DEFENDANT’S MOTION TO DISMISS

UNDERHILL, District Judge.

This proposed class action raises allegations that the prescription drug benefit offered by the defendant, Physicians Health Services of Connecticut, Inc. (“PHS”), uses a drug formulary that obstructs enrollees’ access to prescription medications that their physicians believe are most safe and effective. The plaintiff, State of Connecticut (“Connecticut” or “the State”), has brought suit in its capacity as parens patriae and as the assignee of certain individual PHS enrollees. The State asserts claims for equitable relief pursuant to Section 502(a)(3) of the Employee Retirement Income Security Act of 1974 (“ERISA”), 29 U.S.C. § 1132(a)(3), which permits a “participant, beneficiary, or fiduciary” in a health care plan established pursuant to ERISA to bring an action “to enjoin any act or practice which violates any provision ... of the plan, or ... to obtain appropriate equitable relief.” Currently pending is the defendant’s January 24, 2000 Motion to Dismiss, brought pursuant to Rule 12(b)(6) of the Federal Rules of Civil Procedure.

The fundamental issue raised by the motion to dismiss is whether the State of Connecticut has standing, either under the doctrine of parens patriae or as the assignee of rights of various named participants, to bring an ERISA civil enforcement action under section 502(a)(3). Congress carefully limited the persons authorized to bring an ERISA civil enforcement action, and any such plaintiff must be either “a participant, beneficiary, or fiduciary.” The State does not meet any of these statutory requirements of standing, and cannot overcome its omission from section 502(a)(3) either through the doctrine of parens patriae or through assignment of rights from persons who would have standing. Accordingly, the defendant’s motion to dismiss (doc. # 10) is granted.

I. Background

In its complaint, the State alleges that PHS uses a drug formulary that obstructs enrollees’ access to prescription medications that their physicians believe are most safe and effective. The State’s principal allegations regarding PHS’ drug for-mulary system can be paraphrased as follows:

(1) PHS uses a prior approval process that pressures physicians and patients into using medications that PHS prefers. If a medication is not preferred, PHS will deny coverage unless the physician submits and PHS approves a prior approval request. Prior approval may be granted if PHS determines that the non-preferred drug is medically necessary for the particular patient. •
(2) PHS’ determination whether a drug is “preferred,” is based largely on cost factors rather than effectiveness.
(3) Physicians and enrollees are pressured to accept a preferred drug even when it is not the drug originally prescribed by the physician and even when the preferred drug is less safe and less effective than the drug originally prescribed.
(4) PHS uses a variety of techniques to persuade physicians and enrollees to “switch” from a prescribed drug to a preferred drug, including the denial of coverage for non-preferred drugs and the imposition of onerous prior-approval paperwork.

See Compl. at 2-3, ¶ 3.

The State alleges that, although ERISA requires PHS to fully inform enrollees about the nature of their health plan benefits, PHS has failed to disclose the nature of the formulary system. Connecticut also alleges that, although ERISA requires that an enrollee receive written notice when coverage for a plan benefit is denied, including instructions on how to appeal, PHS fails to give enrollees any notice at all. Accordingly, the State claims that PHS has violated its fiduciary duty under *498 ERISA to administer its health plan solely in the interest of its enrollees and has injured enrollees by maintaining a drug formulary in a manner that serves its own financial interest.

The complaint sets forth three claims. The first claim alleges that PHS has breached its fiduciary duty under ERISA. The State alleges that PHS is a “fiduciary” as that term is defined in ERISA section 3(21)(A), 29 U.S.C. § 1003(21)(A), and that ERISA section 404(a)(1), 29 U.S.C. § 1104(a)(1), requires a fiduciary to discharge its duties “solely in the interest of participants [employees] and beneficiaries [their dependents].” See Compl. at 27, ¶ 83. The State claims that PHS has breached its fiduciary duty to enrollees by obstructing enrollees’ access to safe, effective and medically necessary prescription medications. Id.

The second claim alleges that PHS breached certain ERISA disclosure obligations. Specifically, the State alleges that:

ERISA requires that each plan participant and beneficiary shall be given a summary plan description written in a manner calculated to be understood by the average plan participant, sufficiently accurate and comprehensive to reasonably apprise participants of their rights and obligations under the plan and containing, among other things, information regarding the plan’s requirements respecting eligibility for participation and benefits and the circumstances which may result in disqualification, ineligibility or denial or loss of benefits. • ERISA § 102, 29 U.S.C. § 1022. In addition, ERISA § 104(b), 29 U.S.C. § 1024(b), requires that a summary description of any reductions in covered services must be provided to participants and beneficiaries within 60 days after the changes are adopted.

Compl. at 27, ¶ 85. The State alleges that PHS fails to disclose to enrollees the information required by these provisions. The State claims, for example, that PHS fails to disclose that:

(a) PHS lists prescription drugs as preferred not because of their effectiveness but because of their low cost. The preferred drugs are inexpensive because the defendant has received discounts and rebates from pharmaceutical companies in exchange for including their drugs on the preferred list.
(b) PHS will deny coverage for a prescribed medication even though the preferred substitute may be less safe or less effective.
(c) PHS makes no individualized determination whether the medication prescribed by the attending physician is medically necessary for that particular patient unless the attending physician somehow learns of the denial and initiates a time consuming “prior approval process.”
(d) When it denies coverage for a non-preferred medication PHS does not inform the attending physician.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

State of Missouri v. Kamala Harris
847 F.3d 646 (Ninth Circuit, 2016)
Connecticut v. American Elec. Power Co., Inc.
582 F.3d 309 (Second Circuit, 2009)
The QUAPAW TRIBE OF OKLAHOMA v. Blue Tee Corp.
653 F. Supp. 2d 1166 (N.D. Oklahoma, 2009)
Clearing House Ass'n, LLC v. Spitzer
394 F. Supp. 2d 620 (S.D. New York, 2005)
State of Connecticut v. Health Net, Inc.
383 F.3d 1258 (Eleventh Circuit, 2004)
Jarrow Formulas, Inc. v. International Nutrition Co.
175 F. Supp. 2d 296 (D. Connecticut, 2001)
Table Bluff Reservation v. Philip Morris, Inc.
256 F.3d 879 (Ninth Circuit, 2001)

Cite This Page — Counsel Stack

Bluebook (online)
103 F. Supp. 2d 495, 24 Employee Benefits Cas. (BNA) 2589, 2000 U.S. Dist. LEXIS 12191, 2000 WL 978588, Counsel Stack Legal Research, https://law.counselstack.com/opinion/connecticut-v-physicians-health-services-of-connecticut-inc-ctd-2000.